BR0012666A - Imidazoimidazóis e triazóis como agentes anti-inflamatórios - Google Patents

Imidazoimidazóis e triazóis como agentes anti-inflamatórios

Info

Publication number
BR0012666A
BR0012666A BR0012666-7A BR0012666A BR0012666A BR 0012666 A BR0012666 A BR 0012666A BR 0012666 A BR0012666 A BR 0012666A BR 0012666 A BR0012666 A BR 0012666A
Authority
BR
Brazil
Prior art keywords
inflammatory agents
imidazoimidazoles
triazoles
inflammatory
imidazoimidazols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0012666-7A
Other languages
English (en)
Inventor
Jiang-Ping Wu
Terence Alfred Kelly
Rene M Lemieux
Daniel R Goldberg
Jonathan Emilian Emeigh
Ronald J Sorcek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BR0012666A publication Critical patent/BR0012666A/pt
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: "IMIDAZOIMIDAZóIS E TRIAZóIS COMO AGENTES ANTI-INFLAMATóRIOS". Compostos de fórmula (I) que são úteis para o tratamento ou prevenção de doenças inflamatórias e mediadas por célula imune.
BR0012666-7A 1999-07-21 2000-07-12 Imidazoimidazóis e triazóis como agentes anti-inflamatórios Pending BR0012666A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14490599P 1999-07-21 1999-07-21
US15093999P 1999-08-26 1999-08-26
PCT/US2000/018884 WO2001007440A1 (en) 1999-07-21 2000-07-12 Imidazoimidazoles and triazoles as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
BR0012666A true BR0012666A (pt) 2002-04-09

Family

ID=26842483

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012666-7A Pending BR0012666A (pt) 1999-07-21 2000-07-12 Imidazoimidazóis e triazóis como agentes anti-inflamatórios

Country Status (33)

Country Link
US (3) US6492408B1 (pt)
EP (1) EP1216247B1 (pt)
JP (1) JP2003505460A (pt)
KR (2) KR100767200B1 (pt)
CN (1) CN1166667C (pt)
AR (1) AR029383A1 (pt)
AT (1) ATE413402T1 (pt)
AU (1) AU776496B2 (pt)
BG (1) BG65865B1 (pt)
BR (1) BR0012666A (pt)
CA (1) CA2383017A1 (pt)
CO (1) CO5180640A1 (pt)
CZ (1) CZ2002191A3 (pt)
DE (1) DE60040751D1 (pt)
DK (1) DK1216247T3 (pt)
EA (1) EA004932B1 (pt)
EE (1) EE04965B1 (pt)
ES (1) ES2316374T3 (pt)
HK (1) HK1048637B (pt)
HR (1) HRP20020051A2 (pt)
HU (1) HUP0203971A3 (pt)
IL (2) IL147296A0 (pt)
MX (1) MXPA02000540A (pt)
MY (1) MY155218A (pt)
NO (1) NO322707B1 (pt)
NZ (1) NZ517217A (pt)
PL (1) PL352755A1 (pt)
RS (1) RS50260B (pt)
SK (1) SK286912B6 (pt)
TR (1) TR200200160T2 (pt)
TW (1) TWI261591B (pt)
UY (1) UY26249A1 (pt)
WO (1) WO2001007440A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
JP2004505978A (ja) 2000-08-09 2004-02-26 ベーリンガー　インゲルハイム　ファーマシューティカルズ　インコーポレイテッド （Ｒ）−３−（４−ブロモベンジル）−１−（３，５−ジクロロフェニル）−５−ヨード−３−メチル−１−Ｈ−イミダゾ［１，２−ａ］イミダゾール−２−オンの合成
WO2002050080A1 (en) * 2000-12-19 2002-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
CN1499972A (zh) 2001-01-26 2004-05-26 ����˹�ж�-����˹˹������˾ 用作促肾上腺皮质激素释放因子抑制剂的咪唑基衍生物
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
EP1405852B9 (en) * 2001-06-20 2013-03-27 Daiichi Sankyo Company, Limited Diamine derivatives
BR0211565A (pt) * 2001-08-09 2004-06-29 Daiichi Seiyaku Co Derivados de diamina
FR2829766A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives d'oxamates comportant un heterocycle azote diversement substitue
AU2003282510A1 (en) 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
EP1712553A3 (en) * 2002-10-30 2006-11-02 Boehringer Ingelheim Pharmaceuticals, Inc. Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2005264917A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase
CN1968945A (zh) * 2004-06-16 2007-05-23 惠氏公司 用于抑制β分泌酶的氨基－5,5－二苯基咪唑酮衍生物
MX2007000907A (es) * 2004-07-27 2007-04-13 Boehringer Ingelheim Int Sintesis de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-sulfonico.
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
AU2005295821A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Carboxylic acid peri - substituted bicyclics for occlusive artery disease
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
BRPI0606690A2 (pt) * 2005-01-14 2009-07-14 Wyeth Corp composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
BRPI0607094A2 (pt) * 2005-02-01 2009-08-04 Wyeth Corp composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica
KR20070102751A (ko) 2005-02-14 2007-10-19 와이어쓰 β-세크레타제 억제제로서의 아졸릴아실구아니딘
WO2006107923A1 (en) * 2005-04-05 2006-10-12 Boehringer Ingelheim International Gmbh Substituted benzylimidazoles useful for the treatment of inflammatory diseases
CA2603214A1 (en) * 2005-04-06 2006-10-12 Steven Richard Brunette Derivatives of[6,7-dihydro-5himidazo[1,2-alpha]imidazole-3-sulfonyl]-azetedine-carboxylic acids, esters and amides and use thereof as anti-inflammatory agents
BRPI0610354A2 (pt) * 2005-05-19 2010-06-15 Boehringer Ingelheim Internac derivados de ácido 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-slfÈnico, bem como composição farmacêutica e uso dos mesmos
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
AU2006266167A1 (en) * 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CA2623245A1 (en) * 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
EP1966185A2 (en) * 2005-12-19 2008-09-10 Wyeth a Corporation of the State of Delaware 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION
JP2009525964A (ja) * 2006-01-20 2009-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−スルホン酸アミドの合成
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2032542A2 (en) 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
EP2064201A2 (en) * 2006-09-21 2009-06-03 Wyeth Indolylalkylpyridin-2-amines for the inhibition of beta-secretase
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
PE20090160A1 (es) * 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
AR065814A1 (es) * 2007-03-23 2009-07-01 Wyeth Corp Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados.
SI2225238T1 (sl) * 2007-11-29 2014-12-31 Boehringer Ingelheim International Gmbh Derivati amidov 6,7-dihidro-5H-imidazo(1,2-a)imidazol-3-karboksilne kisline
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
JP5384733B2 (ja) 2009-06-02 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−カルボン酸アミドの誘導体
MX2011012717A (es) * 2009-06-02 2011-12-14 Boehringer Ingelheim Int Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazo l-3-carboxilico.
WO2011002816A1 (en) 2009-06-29 2011-01-06 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
US8785450B2 (en) 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
EP2651898B1 (en) 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
EP2655350B1 (en) 2010-12-21 2016-03-09 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
PL3406251T3 (pl) 2011-05-03 2024-04-29 Agios Pharmaceuticals, Inc. Aktywatory kinazy pirogronianowej do stosowania w terapii
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
PL2731949T3 (pl) * 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
GB201218084D0 (en) 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2016201227A1 (en) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2015493A1 (pt) 1968-08-12 1970-04-30 Sumitomo Chemical Co
DK123717B (da) 1968-11-25 1972-07-24 Sumitomo Chemical Co 3-(3',5'-Dihalogenphenyl)-imidazolidin-2,4-dionderivater med mirobicid virkning.
DE2100800A1 (de) 1970-01-12 1971-07-15 Sumitomo Chemical Co Ltd , Osaka (Japan) Verfahren zur Herstellung von cycli sehen Arylimiden
JPS5136332B1 (pt) 1970-12-09 1976-10-07
JPS5188631A (en) 1975-01-31 1976-08-03 Hiiryoyosatsukinzai oyobi sonoseizoho
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
JPS60246374A (ja) 1984-05-18 1985-12-06 Daicel Chem Ind Ltd ２−アミノイミダゾリン化合物の製造方法
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US4977270A (en) 1988-12-01 1990-12-11 Ici Americas Inc. Substituted 2,4-dioxodiazolidines and -thiadiazolidines and their use as herbicides
US4911748A (en) 1988-12-22 1990-03-27 Ici Americas Inc. Herbicidal 5-substituted-3-phenyl-imidazolidine-2,4-diones
JPH04273877A (ja) * 1991-02-28 1992-09-30 Sumitomo Pharmaceut Co Ltd 新規なイミダゾール誘導体
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
WO1998039303A1 (en) * 1997-03-03 1998-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
AR013445A1 (es) 1997-08-28 2000-12-27 Novartis Ag Antagonistas de lfa-1
JP2002509881A (ja) 1998-03-27 2002-04-02 ジェネンテク・インコーポレイテッド Ｃｄ１１／ｃｄ１８接着レセプター媒介疾患の治療用アンタゴニスト
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
MXPA02000625A (es) * 1999-07-21 2002-07-02 Boehringer Ingelheim Pharma Pequenas moleculas utiles en el tratamiento de enfermedades inflamatorias.
US6852748B1 (en) 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US6844360B2 (en) 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
CA2603214A1 (en) 2005-04-06 2006-10-12 Steven Richard Brunette Derivatives of[6,7-dihydro-5himidazo[1,2-alpha]imidazole-3-sulfonyl]-azetedine-carboxylic acids, esters and amides and use thereof as anti-inflammatory agents
BRPI0610354A2 (pt) 2005-05-19 2010-06-15 Boehringer Ingelheim Internac derivados de ácido 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-slfÈnico, bem como composição farmacêutica e uso dos mesmos

Also Published As

Publication number Publication date
EP1216247A1 (en) 2002-06-26
DK1216247T3 (da) 2009-02-23
EE04965B1 (et) 2008-02-15
TR200200160T2 (tr) 2002-10-21
AU6209100A (en) 2001-02-13
NO20020275L (no) 2002-02-04
ES2316374T3 (es) 2009-04-16
NO20020275D0 (no) 2002-01-18
SK2562002A3 (en) 2002-07-02
YU3902A (sh) 2006-01-16
US20030203955A1 (en) 2003-10-30
PL352755A1 (en) 2003-09-08
MY155218A (en) 2015-09-30
IL147296A0 (en) 2002-08-14
CO5180640A1 (es) 2002-07-30
US6689804B2 (en) 2004-02-10
EE200200028A (et) 2003-04-15
HUP0203971A3 (en) 2005-01-28
CN1166667C (zh) 2004-09-15
KR20070053363A (ko) 2007-05-23
EA004932B1 (ru) 2004-10-28
EA200200097A1 (ru) 2002-08-29
AU776496B2 (en) 2004-09-09
HRP20020051A2 (en) 2003-10-31
KR20020015074A (ko) 2002-02-27
AR029383A1 (es) 2003-06-25
BG106312A (bg) 2002-09-30
EP1216247B1 (en) 2008-11-05
MXPA02000540A (es) 2002-07-02
ATE413402T1 (de) 2008-11-15
HUP0203971A2 (hu) 2003-03-28
RS50260B (sr) 2009-07-15
CN1372562A (zh) 2002-10-02
CA2383017A1 (en) 2001-02-01
BG65865B1 (bg) 2010-03-31
IL147296A (en) 2006-07-05
JP2003505460A (ja) 2003-02-12
NZ517217A (en) 2004-02-27
US20040116426A1 (en) 2004-06-17
WO2001007440A1 (en) 2001-02-01
US7550494B2 (en) 2009-06-23
UY26249A1 (es) 2001-01-31
SK286912B6 (sk) 2009-07-06
HK1048637A1 (en) 2003-04-11
US6492408B1 (en) 2002-12-10
DE60040751D1 (de) 2008-12-18
CZ2002191A3 (cs) 2002-04-17
HK1048637B (zh) 2005-02-25
NO322707B1 (no) 2006-11-27
KR100767200B1 (ko) 2007-10-17
TWI261591B (en) 2006-09-11

Similar Documents

Publication Publication Date Title
BR0012666A (pt) Imidazoimidazóis e triazóis como agentes anti-inflamatórios
BR9914044A (pt) ésteres tetrahidropirido
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
DK0842934T3 (da) 5-HT1F agonister
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
NO20032254D0 (no) Forbindelser for inhibering av ekspresjon av VACM-I
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
PT705100E (pt) Guanidinas substituidas terapeuticas
PT863891E (pt) (metilsulfonil)fenil-2-(5h)furanonas como inibidores de cox-2
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
SE0302304D0 (sv) Novel compounds
BR0010546A (pt) Terapia antiinflamatória para infecção mediada inflamatória
SE9801494D0 (sv) Novel use
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
EE9800230A (et) Difenüülstilbeenid kui COX-2 inhibiitorite eelravimid
ID25478A (id) Agonis 5-ht1f
TR200001026T2 (tr) Nötrofil elastaz inhibitörü olarak pirolopirolon türevleri.
BR9902347A (pt) Azabiciclos como inibidores de rotomase
BR0015121A (pt) Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements